BioVie Inc.

BioVie Inc. is a clinical-stage company that develops innovative drug therapies for neurological and neurodegenerative disorders and advanced liver disease. The company's neurodegenerative disease programs include NE3107, also known as bezisterim. Bezisterim is an investigational, novel, orally administered small molecule. It is believed to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades through a novel mechanism of action. The company acquired the biopharmaceutical assets related to bezisterim from NeurMedix, Inc. in June 2021. Bezisterim is thought to inhibit the activation of inflammatory extracellular signal-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), including interactions with tumor necrosis factor (TNF) signaling and other relevant inflammatory pathways. These pathways are believed to lead to neuroinflammation and insulin resistance. By binding to ERK and selectively modulating NFκB activation and TNF-α production without interfering with their homeostatic functions, bezisterim may offer clinical improvements in conditions such as Parkinson's disease (PD), Alzheimer's disease (AD), and long COVID. Chronic neuroinflammation, insulin resistance, and oxidative stress are common features in major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and Amyotrophic lateral sclerosis. Bezisterim (NE3107) is an investigational oral small molecule that is blood-brain permeable, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties. These properties may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.